453 related articles for article (PubMed ID: 31011260)
1. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
[TBL] [Abstract][Full Text] [Related]
2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
[TBL] [Abstract][Full Text] [Related]
4. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
[TBL] [Abstract][Full Text] [Related]
5. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
[TBL] [Abstract][Full Text] [Related]
6. Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission.
Lin X; Qiu Y; Feng R; Chen B; He Y; Zeng Z; Zhang S; Chen M; Mao R
Clin Transl Gastroenterol; 2020 Feb; 11(2):e00135. PubMed ID: 32463625
[TBL] [Abstract][Full Text] [Related]
7. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
Rimola J; Fernàndez-Clotet A; Capozzi N; Rojas-Farreras S; Alfaro I; Rodríguez S; Masamunt MC; Ricart E; Ordás I; Panés J
Aliment Pharmacol Ther; 2020 Nov; 52(10):1563-1573. PubMed ID: 32886809
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
11. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
13. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
14. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
[TBL] [Abstract][Full Text] [Related]
15. Baseline Wall Thickness Is Lower in Mucosa-Healed Segments 1 Year After Infliximab in Pediatric Crohn Disease Patients.
Kang B; Choi SY; Chi S; Lim Y; Jeon TY; Choe YH
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):279-285. PubMed ID: 27050057
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
Cañete F; Mañosa M; Pérez-Martínez I; Barreiro-de Acosta M; González-Sueyro RC; Nos P; Iglesias-Flores E; Gutiérrez A; Bujanda L; Gordillo J; Ríos León R; Casanova MJ; Villoria A; Rodríguez-Lago I; López Serrano P; García-Herola A; Ramírez-de la Piscina P; Navarro-Llavat M; Taxonera C; Barrio J; Ramos L; Navarro P; Benítez-Leiva O; Calafat M; Domènech E;
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00218. PubMed ID: 32955190
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with immunomodulators and/or anti-TNF antibodies.
Moreno N; Ripollés T; Paredes JM; Ortiz I; Martínez MJ; López A; Delgado F; Moreno-Osset E
J Crohns Colitis; 2014 Sep; 8(9):1079-87. PubMed ID: 24613399
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Reinisch W; Colombel JF; D'Haens G; Sandborn WJ; Rutgeerts P; Geboes K; Petersson J; Eichner S; Zhou Q; Robinson AM; Read HA; Thakkar R
J Crohns Colitis; 2017 Apr; 11(4):425-434. PubMed ID: 27815351
[TBL] [Abstract][Full Text] [Related]
20. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Bertani L; Fornai M; Fornili M; Antonioli L; Benvenuti L; Tapete G; Baiano Svizzero G; Ceccarelli L; Mumolo MG; Baglietto L; de Bortoli N; Bellini M; Marchi S; Costa F; Blandizzi C
Aliment Pharmacol Ther; 2020 Jul; 52(2):284-291. PubMed ID: 32506635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
